Background HIF-1alpha plays a key role in the development and progression of cancer. Its polymorphic variants C1772T and G1790A have been associated with greater susceptibility to cancer and increased tumor progression. Methods We determined the distribution of these polymorphisms among 121 patients with glottic cancer and 154 healthy volunteers by PCR-RFLP. We also analyzed the relationship between the presence of these polymorphisms and various clinicopathologic variables.
Introduction
Spain is one of the countries with the highest incidence of laryngeal cancer [1] . Patients with laryngeal cancer of similar clinicopathologic features and who are undergoing the same treatment can progress in very different ways. Some authors believe that genetic studies and molecular techniques should be combined with classic clinicopathologic criteria (TNM staging and conventional histopathology) to improve accuracy in diagnosis, treatment, and prognosis [2, 3] .
The tumor microenvironment plays a fundamental role in disease progression and response to treatment. Tissue hypoxia is present to a relevant extent in about 50 % of all solid tumors, and appears to act by promoting genetic instability, tumor cell invasiveness, and metastasis, thus worsening prognosis and diminishing the response to chemotherapy and radiotherapy [4] .
Hypoxia-inducible factor (HIF-1) is expressed in most solid tumors in response to low oxygen concentrations [5, 6] . HIF-1 is a heterodimer consisting of a HIF-1 beta subunit and a subunit of oxygen-dependent HIF-1alpha. Its gene is located on chromosome 14q21-24 [7] . HIF-1alpha activates over 60 genes involved in mechanisms related to adaptation and cell survival in situations of hypoxia, such as regulation of pH, anaerobic glycolysis, angiogenesis, and cell proliferation [5] . In squamous-cell carcinoma of the head and neck, the aneuploid characteristic of tumor cells can also favor overexpression of HIF-1alpha in normoxia [8] .
The HIF-1alpha polymorphisms C1772T and G1790A are the result of substitutions of cytosine (C) for thymidine (T) and guanine (G) for adenine (A) at positions 1,772 and 1,790 in exon 12 of the HIF-1alpha gene, respectively [9] . These changes have been observed to produce a more stable HIF-1alpha molecule, are more capable of transactivation, and have been associated with increased susceptibility to cancer and increased tumor progression [7, 10] .
The aim of this study is to determine and compare the frequency of C1772T and G1790A in patients with glottic laryngeal cancer and healthy volunteers. In addition, we assess the presence of these polymorphisms in the progression of glottic laryngeal cancer. We analyze the relationship between these polymorphisms and clinicopathologic variables such as size, lymph node involvement, histologic grade, recurrence, and the presence of second primary tumors. We also determine the association with overall survival (OS) and disease-free survival (DFS).
Materials and methods

Patients
We performed a retrospective study of 121 patients with no prior treatment who were undergoing surgery for squamous-cell carcinoma of the glottis between 1992 and 2008 in the Department of Otolaryngology, Hospital Universitario de La Princesa, Universidad Autónoma de Madrid (UAM), Madrid, Spain. Clinical and pathological data were obtained from the archives of the Departments of Pathology and Otolaryngology, Hospital Universitario de La Princesa. The margins of resection were negative in all cases. All patients in these series were smokers. These characteristics are summarized in Table 1 .
Tumors were staged according to the American Joint Committee on Cancer/Union Internationale Contre le Cancer (AJCC/UICC) 6th edition TNM Staging System [11] . The histologic tumor grade was differentiated according to the World Health Organization grading system. Information on histologic grade was available from 104/121 patients. Eleven patients were subsequently treated with radiotherapy.
Mean (±SD) age was 64 ± 9 years (range, 41-88 years). Median followup was 73 months (6-210 months). All patients were smokers.
The study also included a sample of 154 healthy volunteers (60 % male-40 % women; mean age, 36 years [±15.6 years; range, 19-78 years]) who attended as visitors at the Hospital Universitario de La Princesa and who agreed to participate by signing an informed consent form. We requested authorization to the bioethics committee for the study; considering that this is a retrospective study, we gave informed consent to all the living patients who we achieved a contact for the use of their biologic samples.
Definition of second primary tumor (SPT) and relapse
The definition of second primary tumors (SPT) met the criteria established by Warren and Gates [12] . In addition, we also considered as SPT squamous-cell carcinomas of the larynx that appeared after at least 3 years of the index tumor diagnosis. Only patients with SPT diagnosed clinically and by imaging and histopathology were included in the study. Relapse was considered recurrence of disease within the first 3 years after the initial tumor diagnosis.
Determination of C1772T and G1790A genotypes
We studied C1772T and G1790A by means of polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP) analysis. Patient biopsy specimens were fixed in 10 % buffered formalin and embedded in paraffin; volunteer samples were obtained from blood (5 cc extracted by venipuncture).
DNA extraction
DNA extraction from paraffin
Genomic DNA was extracted by heat treatment and subsequent digestion with proteinase K. We warmed 4-lm tissue sections at 100°C for 2 h in Tris 50 mM and Chelex (ion exchange resin). These were then incubated at 55°C for 2 h in proteinase K (400 lg/ml). After proteinase inactivation by heating at 100°C for 15 min, the mix was centrifuged to sediment cellular debris and the supernatant with DNA was transferred to a clean tube.
DNA extraction from blood
We used a commercial kit (PureGene Kit, Gentra Systems, Minneapolis, Minnesota, USA) according to the manufacturer's instructions.
PCR amplification
PCR was performed with primers described by Fransen et al. and synthesized by Metabion International AG (Martinsried, Germany). In the case of C1772T, 500 ng of DNA were amplified in a final reaction volume of 50 ll with 7.5 pmol of each primer, 2.5 U of Taq polymerase, 19 reaction buffer, 3 mM MgCl 2 , and 200 mM dNTPs (Biotools B&M Labs, S.A., Madrid, Spain). We performed the amplification reaction using a GeneAmp PCR System 2700 thermocycler (Applied Biosystems, Foster City, CA, USA). The temperature cycles were as follows: initial denaturation (94°C, 5 min), followed by 35 denaturation cycles (94°C, 1 min), annealing of the primers (55°C, 1 min), elongation (72°C, 1 min), and a final elongation step (72°C, 7 min). The size of the amplified product was 147 bp. For G1790A, we used the protocol described by Fransen, yielding an amplicon size of 255 bp [13] .
Restriction fragment length polymorphism analysis
We performed RFLP with 10 ll of PCR product digested with specific restriction endonuclease. In the case of C1772T, we used the enzyme Bsc4I because the C[T substitution affects its recognition sequence (CCN5//-N2GG) in such a way that, when it is intact, we obtain a fragment of 131 bp and another of 19 bp (not displayed in the gel); while in the case of polymorphisms, we obtain the undigested fragment of 147 bp. The amplified product was incubated with four units of restriction endonuclease Bsc4I (New England Biolabs/Biotools B&M Labs., S.A., Madrid, Spain) overnight at 55°C and the fragments were separated by electrophoresis in agarose gel at 2.5 % (Conda Laboratories, Madrid, Spain). The G1790A polymorphism was identified using the RFLP enzyme ACiI (New England Biolabs/IZASA., S.A., Madrid. Spain), the recognition sequence of which is 5 0 C//CGC3 0 ; the fragments obtained by digestion measured 143 and 114 bp and were displayed on agarose at 3 % (See supplementary material 1).
Statistical methods
The descriptive study was performed by calculating the mean, median, and standard deviation for quantitative variables and the percentages for qualitative variables. The association between qualitative variables was analyzed by the Chi-square test and Fisher exact test. The analysis of OS and DFS was performed by the Kaplan-Meier method and the comparison between different subgroups was performed by the log-rank test.
Statistical significance was set at a p value of\0.05. The analysis was performed by means of SPSS version 15.0.
We determined the Hardy-Weinberg equilibrium in healthy volunteers (Chi-square test) by comparing the goodness of fit of observed genotype frequencies with respect to the expected one [14, 15] .
Results
Hardy-Weinberg equilibrium was not maintained for C1772T in healthy volunteers. Nevertheless, the genotypic distribution of this polymorphism in healthy volunteers does not differ from the results published in the HapMap for healthy Caucasian subjects [16, 17] . The healthy volunteers were in Hardy-Weinberg equilibrium for G1790A.
Distribution of the polymorphisms in patients compared to healthy volunteers C1772T was determined in 148 healthy volunteers and 117 patients, and G1790A in 139 healthy volunteers and 111 patients. We did not observe significant differences in the distribution of C1772T and G1790A between patients and healthy volunteers. However, patients carried the homozygous TT variant (12.7 %) more often than healthy volunteers (5.4 %) (p = 0.102). The frequency and distribution of these polymorphisms can be seen in Table 2 . Patients tended to be carriers of the TT variant of C1772T (See supplementary material 2).
Association between polymorphisms of HIF-1alpha and clinicopathologic variables
We found that 30 % of patients with advanced-stage tumors (T3-T4) were carriers of the TT variant of C1772T, compared to only 9 % of patients with early-stage tumors (p = 0.036). In addition, 75 % of T4 patients were carriers of the variant homozygous TT (p = 0.008). No significant differences were found between the GA polymorphism and tumor size. 41.7 % of patients with metastasis (N?) were carriers of the TT polymorphism compared to 9 % of patients with N0 (p = 0.006). In addition, 22.2 % of patients with lymph node metastasis were carrying allele A compared with 2 % of those with no metastasis (N0) (p = 0.032). The presence of the homozygous TT variant and the A allele increased the risk of lymph node involvement to 7.14 (95 % CI, 0.97-13.31) and 14.22 (95 % CI, 1.74-117.17) times, respectively.
Patients with a homozygous TT variant tended to have tumors with a low grade of histologic differentiation (p = 0.123). There was no relationship between allele A and the degree of histologic differentiation. There was no association between the occurrence of relapses and SPT in the presence of the polymorphisms studied (Table 3) A decrease was observed in DFS patients with the homozygous TT variant and allele A carriers although this was not statistically significant (p = 0.367) and (p = 0.259), respectively.
Of the 121 patients, 11 received radiotherapy. In patients who received treatment with radiotherapy, the polymorphisms studied did not affect OS (C1772T, p = 0.893; and G1790A, p = 0.583) or DFS (C1772T, p = 0.51; and G1790A, p = 0.5).
Discussion
The main risk factor for the development of head and neck carcinoma is exposure to tobacco and alcohol. However, only a proportion of individuals exposed to these carcinogens develop this tumor [18, 19] . The concept of susceptibility is increasingly important in the pathogenesis of cancer. The genetic component of this disease is observed in large family studies, which reveal a three to eightfold increased risk of developing head and neck carcinoma in first-degree relatives who have had the tumor [20, 21] . Accumulating evidence from case-control studies supports the hypothesis that genetic susceptibility plays a fundamental role in the development of squamous cell carcinoma of the head and neck [22] . The risk of developing cancer depends on small individual differences in the effectiveness of systems of carcinogen metabolism, DNA repair, cell cycle control and apoptosis, and abnormalities in oncogenes and tumor suppressor genes. However, a combination of these factors seems to play a more likely role in predisposing an individual to cancer [18, 23] .
HIF-1alpha is a major factor in the development and the progression of cancer. Its polymorphic variants (C1772T and G1790A) are the result of a single nucleotide change in its genetic sequence and have been associated with increased susceptibility to cancer and increased tumor progression as seen in studies by Zhao et al. [10] and Tanimoto et al. [7] . These polymorphisms probably act synergistically with others and may play a role in susceptibility and progression of glottic laryngeal cancer.
In the meta-analysis by Zhao et al., which included 4,131 patients and 5,387 controls, found that carriers of the T allele and homozygous carriers of the TT allele had an increased risk of developing cancer at any site. In addition, this increased risk was observed in Caucasian women [10] . Our sample consisted mainly of males, which could explain why statistical significance was not reached.
Tanimoto et al. [7] found that patients carrying the C1772T and G1790A polymorphisms have more vascularized and larger tumors. The high transactivation of polymorphic variants of HIF-1alpha promotes tumor progression. In our study, we observed that the TT variant of the homozygous C1772T polymorphism was significantly associated with advanced tumor size (T3-T4, p = 0.036) and that this relationship was even more evident with larger tumors (T4, p = 0.006).
We observed no effect of G1790A on tumor size. However, in the study by Tanimoto et al. [7] , an effect was observed. This difference may be because ours was a large sample of patients with a tumor at a single location (glottis), whereas that of Tanimoto et al. included a small sample of tumors from different locations within the head and neck. Given the biologic heterogeneity within individual sites of the head and neck, our study avoids location-related bias.
In esophageal cancer, HIF-1alpha has been associated with vascular endothelial growth factor C and the presence of lymph node metastasis [24] . Several studies have shown the relationship between HIF-1alpha and metastasis to locations such as the gallbladder [25] , oropharynx [26] , and oral cavity [27] . To our knowledge, no one has studied the relationship between the presence of the polymorphisms of HIF-1alpha and lymph node metastasis. We observed more lymph node metastasis in carriers of the A allele and homozygous carriers of the T allele ( Table 3 ). The high transactivation capacity of these polymorphic variants implies an increased capacity for tumor progression that would account for the greater presence of lymph node metastasis. Patients with the TT and GA variants had a sevenfold and 14-fold greater risk, respectively, of developing lymph node metastasis. Given the rarity of G1790A, larger-scale studies in carriers of this polymorphism are warranted.
In general, overexpression of HIF-1alpha is associated with decreased OS and DFS although with mixed results. Few studies examine the relationship between the presence of HIF-1alpha polymorphisms and survival. Muñoz-Guerra et al. [28] and Chen et al. [29] found that G1790A was associated with a reduction in DFS in patients with oral squamous cell cancer. We observed a decrease in OS and DFS in patients with these polymorphisms; however, the difference was not statistically significant. Carriers of G1790A showed a marked trend toward decreased OS (p = 0.09). These data agree with those of the authors mentioned above although the low prevalence of this polymorphism means that they must be interpreted with caution.
Of the 121 patients studied, 11 received radiotherapy after surgery. These patients had a lower OS and DFS than those who did not receive radiotherapy (p \ 0.001 and p = 0.01, respectively). This is due to more advanced tumor stage and the subsequent poorer prognosis of patients who required radiotherapy. However, the polymorphisms did not influence OS or DFS in patients who received radiotherapy.
This paper aims to highlight the importance of being a carrier of HIF-1alpha polymorphisms and their relationship with tumor progression in glottic laryngeal cancer. Further studies would consolidate our results. New DNA technology will help to build systems that can simultaneously detect multiple polymorphisms in the genes involved in individual susceptibility and progression of cancer. Genetic profiling could help to identify individuals at high risk of developing cancer (from exposure to external carcinogens), thus making it possible for preventive measures to be implemented and helping clinicians to tailor treatment and prevent side effects [3] .
Conclusion
Ours is the first study to demonstrate the involvement of the polymorphisms C1772T and G1790A of HIF-1alpha in the progression of glottic laryngeal cancer. The presence of the homozygous TT variant of C1772T and the presence of the G1790A polymorphism are associated with lymph node involvement. The presence of the TT variant can influence larger tumor size.
